PureTech Health PLC PRTC's resTORbio Files Public S1 for NASDAQ IPO
January 02 2018 - 1:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
02 January 2018
2 January 2018
PureTech Health plc
PureTech Health Affiliate resTORbio Files Public Registration
Statement for Proposed Initial Public Offering
PureTech Health plc (LSE: PRTC) announced that resTORbio, Inc.,
an affiliate of PureTech Health, has filed a public registration
statement on Form S-1 with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed initial public offering of
shares of its common stock. The number of shares to be offered and
the price range for the offering have not yet been determined. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering. resTORbio intends
to list its common stock under the symbol "TORC" on The Nasdaq
Global Market.
BofA Merrill Lynch, Leerink Partners and Evercore ISI are acting
as joint lead book-running managers for the proposed offering.
Wedbush PacGrow is acting as co-manager.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective. The
offering will be made only by means of a prospectus. When
available, a copy of the preliminary prospectus may be obtained by
visiting the SEC's website at www.sec.gov or by contacting: BofA
Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte NC 28255-0001, Attn: Prospectus Department, or by email
at dg.prospectus_requests@baml.com; Leerink Partners, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525 extension 6132 or by email at
syndicate@leerink.com; or Evercore ISI, Attention: Equity Capital
Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by
telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel
therapeutics for the treatment of aging-related diseases.
resTORbio's lead program focuses on selective inhibition of the
target of rapamycin complex 1 (TORC1) pathway to treat
aging-related diseases with an initial focus on diseases caused by
immunosenescence, the decline in immune function that occurs during
aging. resTORbio's lead product candidate, RTB101, alone or in
combination with everolimus, is in a Phase 2b clinical trial to
evaluate its potential in reducing the incidence of respiratory
tract infections (RTI) in elderly subjects.
Contact:
PureTech Health: Investor Relations:
Allison Mead Talbot FTI Consulting
+1 617 651 3156 Ben Atwell, Rob
amt@puretechhealth.com Winder
+44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADDGDBDBGBGIB
(END) Dow Jones Newswires
January 02, 2018 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024